These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26025565)

  • 1. Measures of follow-up in time-to-event studies: Why provide them and what should they be?
    Betensky RA
    Clin Trials; 2015 Aug; 12(4):403-8. PubMed ID: 26025565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kaplan-Meier curves for survivor causal effects with time-to-event outcomes.
    Chiba Y
    Clin Trials; 2013 Aug; 10(4):515-21. PubMed ID: 23610455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.
    Rosas SR; Schouten JT; Dixon D; Varghese S; Cope MT; Marci J; Kagan JM
    Clin Trials; 2014 Oct; 11(5):553-9. PubMed ID: 24980279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposals on Kaplan-Meier plots in medical research and a survey of stakeholder views: KMunicate.
    Morris TP; Jarvis CI; Cragg W; Phillips PPJ; Choodari-Oskooei B; Sydes MR
    BMJ Open; 2019 Sep; 9(9):e030215. PubMed ID: 31575572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multiple imputation method for sensitivity analyses of time-to-event data with possibly informative censoring.
    Zhao Y; Herring AH; Zhou H; Ali MW; Koch GG
    J Biopharm Stat; 2014; 24(2):229-53. PubMed ID: 24605967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A partially parametric estimator of survival in the presence of randomly censored data.
    Klein JP; Lee SC; Moeschberger ML
    Biometrics; 1990 Sep; 46(3):795-811. PubMed ID: 2242415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New methods for estimating follow-up rates in cohort studies.
    Xue X; Agalliu I; Kim MY; Wang T; Lin J; Ghavamian R; Strickler HD
    BMC Med Res Methodol; 2017 Dec; 17(1):155. PubMed ID: 29191174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival analysis I: the Kaplan-Meier method.
    Stel VS; Dekker FW; Tripepi G; Zoccali C; Jager KJ
    Nephron Clin Pract; 2011; 119(1):c83-8. PubMed ID: 21677442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
    Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
    Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fair comparisons of cause-specific and relative survival by accounting for the systematic removal of patients from risk-sets.
    Wells M; Rutherford MJ; Lambert PC
    Cancer Epidemiol; 2023 Oct; 86():102408. PubMed ID: 37591148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating a population cumulative incidence under calendar time trends.
    Hansen SN; Overgaard M; Andersen PK; Parner ET
    BMC Med Res Methodol; 2017 Jan; 17(1):7. PubMed ID: 28077076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival analysis using auxiliary variables via non-parametric multiple imputation.
    Hsu CH; Taylor JM; Murray S; Commenges D
    Stat Med; 2006 Oct; 25(20):3503-17. PubMed ID: 16345047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of the censoring distribution in clinical trials.
    Jiang S; Swanson D; Betensky RA
    Contemp Clin Trials Commun; 2021 Sep; 23():100842. PubMed ID: 34504980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the Effects of Early Censoring and Analysis of Clinical Trial Survival Data on Effectiveness and Cost-effectiveness Estimation through a Case Study in Advanced Breast Cancer.
    Bagust A; Beale SJ
    Med Decis Making; 2018 Oct; 38(7):789-796. PubMed ID: 30125510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIS-based Kaplan-Meier plots--a single source approach for documenting and reusing routine survival information.
    Breil B; Semjonow A; Müller-Tidow C; Fritz F; Dugas M
    BMC Med Inform Decis Mak; 2011 Feb; 11():11. PubMed ID: 21324182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competing risk bias was common in Kaplan-Meier risk estimates published in prominent medical journals.
    van Walraven C; McAlister FA
    J Clin Epidemiol; 2016 Jan; 69():170-3.e8. PubMed ID: 26232083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A hybrid approach to predicting events in clinical trials with time-to-event outcomes.
    Fang L; Su Z
    Contemp Clin Trials; 2011 Sep; 32(5):755-9. PubMed ID: 21645644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods to Analyse Time-to-Event Data: The Kaplan-Meier Survival Curve.
    D'Arrigo G; Leonardis D; Abd ElHafeez S; Fusaro M; Tripepi G; Roumeliotis S
    Oxid Med Cell Longev; 2021; 2021():2290120. PubMed ID: 34594473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reporting of loss to follow-up information in randomised controlled trials with time-to-event outcomes: a literature survey.
    Vervölgyi E; Kromp M; Skipka G; Bender R; Kaiser T
    BMC Med Res Methodol; 2011 Sep; 11():130. PubMed ID: 21936924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of the discrete-time Kaplan-Meier estimate to nonignorable censoring: Application in a clinical trial.
    Liu T; Heitjan DF
    Stat Med; 2012 Nov; 31(25):2998-3010. PubMed ID: 22806989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.